214 studies on Liraglutide curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Liraglutide's antihypertensive time course and mechanism are being evaluated in 35 hypertensive type 2 diabetes patients via a dose-titration regimen.
While specific findings are not yet available, this research addresses a critical gap in understanding how GLP-1 mimetics influence central reward pathways and food selection. If liraglutide is found to alter brain re…
This replication effort is crucial for advancing the utility of real-world evidence (RWE) in clinical practice and research. Clinicians and researchers will gain clearer guidance on when and how to confidently interpr…
A study compared the efficacy and glycemic control effects of Dulaglutide versus Liraglutide in obese Type 2 diabetic adolescents already using metformin.
Understanding how liraglutide specifically modulates brain reward circuits could refine obesity treatment strategies, moving beyond general appetite suppression to more targeted interventions. For peptide users and cl…
If future research confirms a positive effect, liraglutide could represent a valuable adjunctive therapy for Type 1 Diabetes, potentially improving glycemic control, preserving residual beta-cell function, and reducin…
Dulaglutide reduced stroke risk by 23% (RR: 0.77) and semaglutide lowered cardiovascular mortality by 26% (RR: 0.74) in T2DM patients, a network meta-analysis of 67,769 found.
Liraglutide's efficacy for glycemic control was compared against metformin monotherapy and metformin/glimepiride combination in 1091 Type 2 Diabetes patients.
Should this trial demonstrate that Insulin Degludec/Liraglutide (IDegLira) significantly improves Time in Range while simultaneously reducing markers of inflammation and endothelial dysfunction compared to a tradition…
Clinical trial NCT01451905 aims to characterize GLP-1 receptors in psoriatic skin and evaluate liraglutide for reducing psoriasis severity.
A completed observational study (NCT07374445) explored optimal liraglutide timing for patients remaining obese six months post-metabolic surgery.
For patients with severe insulin resistance in Type 2 Diabetes, optimizing glycemic control without excessive insulin burden is a critical challenge. High insulin doses often lead to weight gain and hypoglycemia, limi…
A completed Phase 3 trial (NCT04074161) compared semaglutide 2.4 mg weekly to liraglutide 3.0 mg daily for weight management in overweight/obese adults over 68 weeks.
For nursing mothers prescribed liraglutide, this information highlights a critical knowledge gap: the absence of direct clinical data on infant exposure via breast milk. Clinicians and mothers must exercise caution, e…
Liraglutide and dapagliflozin's six-month effects on lipid profiles, cardiovascular risk, and NT-proBNP in MASLD patients were assessed.
This analysis highlights insulin resistance as a crucial biomarker for predicting liraglutide's efficacy in preventing recurrent stroke and vascular events in type 2 diabetes patients. For clinicians and biohackers, t…
This narrative review highlights the critical need for further research into the effects of GLP-1 agonists on bone health and orthopedic surgery outcomes. Clinicians should be aware of the limited current evidence reg…
This study introduces a powerful SPRM methodology for characterizing peptide-receptor interactions directly on live cells, offering a significant advancement over traditional methods. This label-free, real-time approa…
Adjunctive liraglutide therapy reduced 12-month atrial fibrillation recurrence by up to 92% post-ablation in overweight/obese patients, linked to epicardial adipose tissue reduction.
Liraglutide significantly upregulated GLP1R expression and activated cAMP/PKA signaling, inducing apoptosis and cell cycle arrest in MCF7 breast and PC-3 prostate cancer cells.
This review highlights the critical need for individualized perioperative management protocols for patients on GLP-1RAs. Clinicians should avoid routine discontinuation of GLP-1RAs before surgery, instead focusing on …
This analysis highlights a critical shift in the clinical research paradigm for GLP-1 agonists in obesity, moving beyond primary weight loss to encompass a wider spectrum of metabolic and organ-specific benefits. Clin…
This review underscores a paradigm shift in metabolic disease management, moving beyond single-target approaches to powerful multi-agonist strategies. For individuals managing T2DM, obesity, or MASLD, the emergence of…
This Phase 3 trial represents a crucial step in exploring Liraglutide as an adjunctive therapy for Type 1 Diabetes, a population with significant unmet needs beyond insulin. If the study's hypotheses were confirmed, i…
If successful, this trial could represent a significant paradigm shift in managing Type 1 Diabetes Mellitus, moving beyond mere symptom management to actively preserving endogenous insulin production. For individuals …
Clinicians and individuals using liraglutide should be aware of the rare but serious risk of acute pancreatitis, especially in populations with pre-existing risk factors for pancreatic disease or specific genetic pred…
Understanding Liraglutide's effect on angiogenesis biomarkers is critical for refining Type 2 Diabetes treatment strategies, especially concerning micro- and macrovascular complications. If Liraglutide positively infl…
While specific results are not available from this abstract, the completion of a Phase IIb trial for MEDI0382 in Type 2 Diabetes Mellitus and obesity signals progress in developing new treatment options. If successful…
If positive results emerge from this completed Phase 3 trial, liraglutide could become a significant therapeutic option for pediatric patients with Prader-Willi Syndrome, addressing the severe obesity and hyperphagia …
Liraglutide's ability to improve insulin secretion, reduce exogenous insulin requirements, and its safety in early-diagnosed Type 1 Diabetes patients (10-30 years) was investigated in a Phase 2 trial.
The HARRP program's successful replication of major T2DM trials with real-world data would significantly strengthen the evidence base for established treatments like Canagliflozin, Liraglutide, and Saxagliptin. This i…
While this specific trial was withdrawn without data, the underlying hypothesis highlights a novel potential therapeutic avenue for monoclonal gammopathies by targeting epicardial fat and lipid metabolism. Liraglutide…
While specific results are not available in this record, the investigation itself highlights a critical area for Type 2 Diabetes management. If liraglutide were shown to significantly reduce postprandial triglycerides…
This trial represents a crucial step in exploring preventative strategies for Type 1 Diabetes, moving beyond reactive management. If liraglutide proves effective in preserving beta cell function and delaying disease o…
This foundational dataset provides an unprecedented tool for understanding diabetic microvascular disease at a systemic level, moving beyond organ-specific views. For researchers and clinicians, it offers a quantitati…
If GLP-1R agonists are found to significantly reduce Lipoprotein(a) (Lp(a)) levels, it would represent a substantial advancement in managing cardiovascular risk for Type 2 Diabetes patients. This finding would add a n…
If positive, this study could establish a new adjunctive therapy protocol for patients post-sleeve gastrectomy who may experience suboptimal weight loss or weight regain. Combining bariatric surgery with a GLP-1R agon…
Effective strategies for weight loss maintenance are crucial, as regain is a major challenge in obesity management. This trial's design, focusing on subjects who already achieved initial weight loss through diet, dire…
This research suggests a novel therapeutic strategy for hypertension and hyperaldosteronism by combining a GLP-1R agonist with a PDE4 inhibitor. Combining liraglutide with roflumilast could offer enhanced cardiovascul…
Comprehensive understanding of GLP-1RA reproductive safety is paramount for women of reproductive age managing obesity or type 2 diabetes. This review underscores the necessity for robust research to establish clear g…
This optimized mini-tag strategy offers a significant advancement for the scalable and economical production of GLP-1 analogs and other therapeutic peptides. By focusing on mass fraction optimization, which minimizes …
A randomized, double-blind, placebo-controlled trial is evaluating if Liraglutide 3.0 mg's weight loss effects in obesity are mediated by gut microbiome changes.
A sublingual liraglutide formulation could revolutionize T2DM management by offering a highly convenient, non-injectable alternative to current GLP-1R agonists. This would significantly enhance patient adherence and q…
This Phase 2 study is crucial for understanding the potential of liraglutide (a GLP-1 receptor agonist) as a combination therapy for Type 2 Diabetes. The findings, once fully published, could highlight a more effectiv…
While this abstract outlines the study design rather than presenting results, the investigation itself highlights a critical area of unmet need in diabetes management. If liraglutide demonstrates renal protection, it …
The potential implications of a successful neuroprotective agent for Parkinson's Disease are immense, offering hope for slowing or halting disease progression. If liraglutide were shown to be effective, it could repre…
Optimizing treatment strategies for patients with Type 2 Diabetes and poor glycemic control is a critical unmet medical need, as uncontrolled blood sugar significantly increases the risk of severe complications. This …
While specific findings are not yet available, this study's design is crucial for understanding the feasibility of transitioning Type 2 Diabetes patients to sustained-release GLP-1R agonist therapies. If ITCA 650 prov…
A randomized crossover study explored whether liraglutide could enhance coronary microvascular perfusion in 20 Type 2 Diabetes patients.